Recurrence carcinoma

De Palo G, Cerrotta A, Gardani G, et al. Concurrent Radiotherapy and Taxol as Radiosensitizer in Locally Advanced or Recurrent Carcinoma of the Uterine Cervix (abstract 1404). Pro Am Soc Clin Oncol 1998 17 364a. 

Concurrent Chemoradiation for Patients with Locally Advanced or Recurrent Carcinoma of the Vulva... 

Eifel PJ, Morris M, Burke TW, et al. Preoperative continuous infusion cisplatinum and 5-fluoro-uracil with radiation for locally advanced or recurrent carcinoma of the vulva. Gynecol Oncol 1995 59 51-56. 

Heron CW, Husband JE, Williams MP, Dobbs HJ, Cosgrove DO (1988) The value of CT in the diagnosis of recurrent carcinoma of the cervix. Clin Radiol 39 496-501... 

Walsh JW, Amendola MA, Hall DJ, Tisnado J, Goplerud DR (1981) Recurrent carcinoma of the cervix CT diagnosis. AJR Am J Roentgenol 136 117-122... 

Rietbroek RC, Schilthuis MS, Bakker PJ, van Dijk JD, Post-ma AJ, Gonzalez Gonzalez D, Bakker AJ, van der Velden J, Helmerhorst TJ, Veenhof CH (1997) Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix. Cancer 79 935-943... 

LA. Infusion Our experience with percutaneous intraarterial transcatheter chemotherapy in patients with recurrent carcinoma of the vulva and penis is limited. Therapy is usually delivered through the internal pudendal branch of the internal iliac artery, the external pudendal branch of the external iliac artery, and the external pudendal branch of the deep femoral artery. The chemotherapy regimen consisted of mitomycin C (10 mg/m over 24 h), bleomycin (20-40 mg/m over 24 h), and dsplatin (100 mg/m over 2 h). Although the number of patients treated under this regimen is too small for analysis, dramatic responses have been observed in several patients. 

Bleiberg, H., Salhadin, A., and Galand, P., 1977, Cell cycle parameters in human colon Comparison between primary and recurrent carcinomas, benign polyps and adjacent unaffected mucosa. Cancer 39 1190. 

Toyomycin is used clinically in the treatment of reticulum cell sarcoma, recurrent carcinoma of the uterus, and metastic tumour of the lymph nodes... 

Wadler S, Schwartz EL, Haynes H, Rameau R, Quish A, Mandeli J, Gallagher R, Hallam S, Fields A, Goldberg G et al (1997) AW-trans retinoic acid and interferon-a-2a in patients with metastatic or recurrent carcinoma of the uterine cervix. Cancer 79 1574-1580... 

Herpes Simplex. There are two types of herpes simplex vims (HSV) that infect humans. Type I causes orofacial lesions and 30% of the U.S. population suffers from recurrent episodes. Type II is responsible for genital disease and anywhere from 3 x 3 x 10 cases per year (including recurrent infections) occur. The primary source of neonatal herpes infections, which are severe and often fatal, is the mother infected with type II. In addition, there is evidence to suggest that cervical carcinoma may be associated with HSV-II infection (78—80). 

Hepatocellular carcinoma (HCC) develops in patients with chronic liver diseases associated with hepatitis B and hepatitis C vims infections with high incidences. Here, an acyclic retinoid has been shown to suppress the posttherapeutic recurrence after interferon-y or glycerrhicin treatment in cirrhotic patients who underwent curative treatment of preceding tumors. The retinoid induced the disappearance of serum lectin-reactive a-fetoprotein (AFP-L3), a tumor marker indicating the presence of unrecognizable tumors in the remnant liver, suggesting a deletion of such minute (pre)malignant clones (clonal deletion). As a molecular mechanism of the clonal deletion, a novel mechanism of... 

Small cell lung cancer typically presents as extensive disease (approximately 60% to 70% of new cases) and progresses very quickly. Small cell carcinomas are very responsive to chemotherapy and radiation. Radiotherapy became the standard in 1969, when a randomized trial showed that it offered the potential for cure, whereas surgery did not.20 For the vast majority of patients, chemotherapy with or without radiotherapy is the treatment of choice. Even after a complete response to therapy, the cancer usually recurs within 6 to 8 months, and survival time following recurrence is typically short ( 4 months). This yields a typical survival rate of 14 to 20 months for limited disease and 8 to 13 months for extensive disease.33 Table 87-6 illustrates the general treatment path of SCLC. 

Ninety-five percent patients monitored for recurrence show CA 125 concentrations greater than 35 U/ml and residual ovarian carcinoma. However, a negative result is not conclusive because half of the patients with negative results have microscopic residual carcinoma. Therefore, it is essential to have a second-look procedure in order to rule out residual carcinoma. Postsurgical monitoring of patients... 

CEA levels are elevated in benign diseases such as inflammatory bowel disease, chronic gastritis and peptic ulcer, cirrhosis, and hepatitis. CEA testing is recommended primarily to monitor patients after surgery for recurrent colorectal carcinoma. Twenty percent of colorectal carcinomas do not express CEA therefore, immunohistochemical methods are recommended to identify the negative cases. If a 5.0 ng/ml cutoff is used as the detection criterion, approximately 60 to 90 percent of the clinical cases will be detected for recurrences 2 to 10 months prior to clinical symptoms (37, 38). 

Simple or total mastectomy involves removal of the entire breast without dissection of underlying muscle or axillary nodes. This procedure is used for carcinoma in situ where the incidence of axillary node involvement is only 1% or with local recurrence following breast conservation therapy. 

Pinsky, C.M. et al., Intravesical administration of Bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder Report of a prospective, randomized trial, Cancer Treat. Rep., 69,47, 1985. 

Cordon, A.N. et al.. Recurrent epithelial ovarian carcinoma a randomized phase III study of pegylated liposomal doxorubicin versus topotecan, /. Clin. Oncol., 19, 3312-3322,2001. 

ADEPT strategies have been described but only the carboxypeptidase G2 approach has been tested in patients so far. In a phase I clinical trial, patients with non-resectable metastatic or locally recurrent colorectal carcinoma were treated with ADEPT. Carboxypeptidase G2 activity was found in metastatic tumour biopsies. The pro-drug was converted into the active drug but leakage into the bloodstream also occurred [22,144]. 

In the bicalutamide prostate cancer programme, the adjuvant treatment of patients with advanced prostate carcinoma (T1-T4 NO/NX, MO) with bicalutamide (150 mg, once a day) was evaluated. 4052 patients were randomised to bicalutamide with best standard care (either radiation, prostatectomy or watchful waiting ), whereas 4061 patients received a placebo with best standard care. An initial reduction of prostate cancer recurrence, which was observed in an interim analysis, later was not confirmed [219]. As the survival time in the bicalutamide treatment group was decreased, the study was terminated ahead of time. 

Gelmon KA, Tischkowitz M, Mackay H et al (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative hreast cancer a phase 2, multicentre, open-lahel, non-ran-domised study. Lancet Oncol 12 852-861... 

Mahjoubi M, Sadek H, Francois E, et al. Epidermoid anal canal carcinoma (EACC) activity of cisplatin and continuous 5 -fluorouracil in metastatic and/or local recurrent disease. Proc Annu Meet Am Soc Clin Oncol 1990 9 114. 

A similar small phase II trial from Germany has reported on seven patients receiving concurrent chemoradiation for transitional cell carcinoma of the bladder with cisplatin and paclitaxel (96). The authors conclude that this combination is at least feasible given an acceptable acute toxicity profile and reasonable efficacy. Another small series is reported by Nichols et al. (97) where eight patients received radiation with concurrent paclitaxel and carboplatin in an attempt at bladder preservation. Three of the patients remain free of distant metastases, and local recurrence has occurred in three. 

The RTOG has an ongoing phase II study analyzing the use of paclitaxel and cisplatin in combination with split-course concomitant radiotherapy in patients with recurrent squamous cell carcinoma requiring reirradiation. Cisplatin and paclitaxel are administered d 1-... 

Vermorken J, Catimel G, Mulder PD, et al. Randomized phase II trial of weekly methotrexate (MTX) versus two schedules of triweekly paclitaxel (taxol) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). ProcAnnu Meet Am Soc Clin Oncol 1999 18 A 1527. 

---